208例T1-2N1M0期乳腺癌改良根治术患者无病生存情况的危险因素分析

目的探究行改良根治术的T1-2N1M0期乳腺癌患者无病生存的影响因素。 方法回顾性分析2011年1月至2014年11月经改良根治术治疗208例T1-2N1M0期乳腺癌患者资料，统计术后截止2019年11月患者随访情况，并记录患者术后5年肿瘤转移、复发情况，以SPSS 22.00统计学软件进行数据处理。计数资料用[例(%)]表示，组间比较采用χ²检验；乳腺癌患者预后的相关因素行单因素和Cox多因素回归模型分析，P<0.05差异有统计学意义。 结果本次研究中208例患者均获得确切随访，无失访病例。其中复发、转移28例(13.5%)，无转移复发180例(86.5%)，患者5年无病生存率为86.5%；将单因素分析结果具有统计学意义的变量纳入Cox多因素回归模型。结果显示，年龄<45岁、组织学分级为III级、术后放疗、Ki-6 ≥30%为行改良根治术T1-2N1M0期乳腺癌患者复发转移的独立预后因素(P<0.05)。 结论年龄<45岁、组织学分级为III级、术后放疗、Ki-67≥30%是T1-2N1M0期乳腺癌患者行改良根治术后复发转移的独立危险因素，增加患者预后风险。

Risk factors analysis of Disease-Free Survival after modified radical mastectomy in 208 patients with T1-2N1M0 breast cancer

ObjectiveTo investigate the risk factors of disease-free survival rate after modified radical mastectomy in patients with T1-2N1M0 stage breast cancer. MethodsRetrospective analysis were performed in 208 patients with T1-2N1M0 breast cancer underwent modified radical mastectomy from January 2011 to November 2014. The endpoint of follow-up was November 2019 and 5-years survival, of patients metastasis and recurrence of tumors were analyzed, Statistical analysis were performed by using SPSS 22.0 software. Count data were expressed as % and were analyzed by using χ² test. The univariate and Cox multivariate regression models were used to analyze the risk factors of prognosis. A P value<0.05 was considered as statistically significant difference. ResultsIn this study, 208 patients were followed up. Among them, 28 cases had metastatic or recurrence, 180 cases had no metastasis and recurrence, with the 5-year disease-free survival rate of 86.5%. The results of single factor analysis showed that the risk factors of prognosis of patients with T1-2N1M0 breast cancer undergoing modified radical mastectomy included age of <45, Histological grade III, postoperative radiotherapy and Ki-67≥30%, with statistically significant difference (P<0.05). ConclusionAge of <45y, histological grade III, postoperative radiotherapy and Ki-67≥30% are independent risk factors for recurrence and metastasis after modified radical mastectomy in patients with T1-2N1M0 stage breast cancer, which might increase the prognosis risk.